Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Gastric Cancer
Published in: Gastric Cancer 2/2014

01-04-2014 | Original Article

Laparoscopic wedge resection of the stomach for gastrointestinal stromal tumor (GIST): non-touch lesion lifting method

Authors: Hirokazu Kiyozaki, Masaaki Saito, Hirofumi Chiba, Osamu Takata, Toshiki Rikiyama

Published in: Gastric Cancer | Issue 2/2014

Login to get access

Abstract

Background

Laparoscopic surgery for GIST carries a risk of intraoperative tumor dissemination. To avoid tumor dissemination, we have utilized a “non-touch” method for surgical resection of GIST since 2000.

Methods

Forty-two patients with gastric GIST were treated at our institution between 2000 and 2012. Laparoscopic wedge resection of the stomach was used as the standard procedure for tumors that were 2–5 cm in size. Tumors larger than 5 cm were treated with open surgery. Our non-touch procedure included a lesion-lifting method using traction sutures at the normal stomach wall around the tumor. Intraoperative gastroscopy was utilized to confirm the location of the tumor with laparoscopy. After lifting of the tumor, tumors with a clear operative margin were resected using a linear stapler. Tumors located at the posterior wall of the stomach or located near the esophagogastric junction were resected using traction sutures.

Results

Median operative time was 140 min and median blood loss was 0 ml. Postoperative course was uneventful excepting one patient who experienced postoperative bleeding. The median postoperative stay was 7 days. One patient developed liver metastasis after surgery. None of the patients had local recurrence or peritoneal recurrence case.

Conclusion

This non-touch lesion-lifting method was useful for the surgical management of gastric GIST.
Literature
1.
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal tumors recurrence patterns and prognostic factor for survival. Ann Surg. 2000;231(1):51–8.PubMedCentralPubMedCrossRef
2.
Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol. 2005;16:566–78.CrossRef
3.
Demetri GD, Benjamin RS, Blanke CD, Blay YJ, Casali P, Choi H, et al. NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor GIST: Update of NCCN clinical practice guideline. J Natl Compr Canc Netw. 2007;5 (suppl 2):1–28.
4.
Tagaya N, Mikami H, Kogure H, Kubota K, Hosoya Y, Nagai H. Laparoscopic intragastric stapled resection of gastric submucosal tumors located near the esophagogastric junction. Surg Endosc. 2002;16(1):177–9.PubMedCrossRef
5.
Nguyen SQ, Divino CM, Wang JL, Dikman SH. Laparoscopic management of gastrointestinal stromal tumors. Surg Endosc. 2006;20(5):713–6.PubMedCrossRef
6.
Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, et al. Operative indication for relatively small (2–5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery (St. Louis). 2006;139(4):484–92.CrossRef
7.
Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg. 2006;243(6):738–45.PubMedCentralPubMedCrossRef
8.
Hiki N, Yamamoto Y, Fukunaga T, Yamaguchi T, Nunobe S, Tokunaga M, et al. Laparoscopic and endoscopic cooperative surgery for gastrointestinal stromal tumor dissection. 2006;22(7):1729–35.
9.
Nishimura J, Nakajima K, Omori T, Takahashi T, Nishitani A, Ito T, et al. Surgical strategy for gastrointestinal stromal tumors: laparoscopic vs. open resection. Surg Endosc. 2007;21(6):875–8.PubMedCrossRef
10.
Matsui H, Nabeshima K, Okamoto Y, Nakamura K, Kondoh Y, Makuuchi H, et al. Fundic rotation technique: a useful procedure for laparoscopic exogastric resection of gastric submucosal tumor located on the posterior wall near the esophagogastric junction. Tokai J Exp Med. 2011;36(4):152–8.
11.
Tsujimoto H, Yaguchi Y, Kumano I, Takahana R, Ono S, Hase K. Successful gastric submucosal tumor resection using laparoscopic and endoscopic cooperative surgery. World J Surg. 2012;36(2):327–30.PubMedCrossRef
12.
Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–65.PubMedCrossRef
Metadata
Title
Laparoscopic wedge resection of the stomach for gastrointestinal stromal tumor (GIST): non-touch lesion lifting method
Authors
Hirokazu Kiyozaki
Masaaki Saito
Hirofumi Chiba
Osamu Takata
Toshiki Rikiyama
Publication date
01-04-2014
Publisher
Springer Japan
Published in
Gastric Cancer / Issue 2/2014
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-013-0272-8

Other articles of this Issue 2/2014

Gastric Cancer 2/2014 Go to the issue

Original Article

Limited subtotal gastrectomy for early remnant gastric cancer

Editorial

The earlier the better?

Original Article

Treatment selection for gastric cancer with portal hypertension: clinical management

Original Article

Can we apply the same indication of endoscopic submucosal dissection for primary gastric cancer to remnant gastric cancer?

Original Article

Aberrant expression of SOX9 is associated with gastrokine 1 inactivation in gastric cancers

Original Article

Mortalin is a prognostic factor of gastric cancer with normal p53 function
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits